Rayont Inc.

RAYT

US75508M1009

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:19:14 2024-04-15 am EDT			5-day change	1st Jan Change
0.0005 ^USD	+49,900.00%		0.00%	+49,900.00%

2023	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
2023	Rayont Inc. Announces Board Appointments	CI

RAYONT INC. : Financial Statements and Exhibits (form 8-K)

March 31, 2023 at 05:31 pm EDT

Item 9.01 Financial Statements and Exhibits





Number   Description

1.01       On March 28, 2023, Commonwealth Bank of Australia, the lender to
         subsidiaries of Rayont Inc, notified Rayont Holdings Pty Ltd (formerly
         known as No More Knots Holdings) to appoint two receivers.




4

Latest news about Rayont Inc.

Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Rayont Inc. Announces Board Appointments	23-02-24	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-14	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	23-01-17	CI
Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-12-29	CI
Rayont Inc. Auditor Raises 'Going Concern' Doubt	22-12-28	CI
Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	22-05-20	CI
Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-17	CI
Rayont Inc. Announces Management Changes	22-04-25	CI
Rayont Inc. Announces Board Resignations	22-04-22	CI
Rayont Inc. Announces Management Changes	22-03-01	CI
Rayont Inc. Announces Executive Changes	22-03-01	CI
Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-24	CI
Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-15	CI
Rayont, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-17	CI
Rayont Inc. Appoints Leilani Latimer as Non-Executive Director	21-04-22	CI
Rayont, Inc. Announces Appointment of Dhurata Toli as Secretary	21-03-26	CI
Rayont Inc Announces Executive Changes	21-03-25	CI
Rayont, Inc. Announces Management Changes	21-03-25	CI
Rayont Inc Appoints Reyad Fezzani as Non-Executive Director and Chairman of the Board	21-03-15	CI
Rayont, Inc. Changes its Fiscal Year End from July 31 to June 30	21-03-03	CI
Rayont : Earnings Flash (RAYT) RAYONT Reports Q4 Revenue $457,865	21-02-16	MT
Rayont, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	21-02-16	CI
Rayont, Inc. Announces Fiscal Year Change from September 30 to June 30, Effective December 21, 2020	20-12-21	CI
Rayont, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	20-12-18	CI

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAYONT INC.	+49,900.00%	22.87K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B